A randomized, placebo-controlled, blinded, parallel-group clinical trial to assess the efficacy of N-acetylcysteine in adults with acute infections or sepsis and evidence of liver dysfunction: the IMPACT-NAC trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525895-25-00

Enrollment

360

Registered

2026-05-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute infection, Sepsis

Brief summary

Days alive and out of hospital from randomization to day 14

Detailed description

Number of participants with one or more serious adverse event within 14 days of randomization, All-cause mortality at day 180, Health-related quality of life (HRQoL) at day 180 using EQ-5D-5L index values, Admission to an intensive care unit (ICU) within 14 days of admission, Duration of antibiotic therapy from randomization to day 14, Time to clinical stability, Days alive and out of hospital from randomization to day 180

Interventions

DRUGACETYLCYSTEINE

DRUGSODIUM CHLORIDE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Days alive and out of hospital from randomization to day 14	—

Secondary

Measure	Time frame
Number of participants with one or more serious adverse event within 14 days of randomization, All-cause mortality at day 180, Health-related quality of life (HRQoL) at day 180 using EQ-5D-5L index values, Admission to an intensive care unit (ICU) within 14 days of admission, Duration of antibiotic therapy from randomization to day 14, Time to clinical stability, Days alive and out of hospital from randomization to day 180	—

Measure

Time frame

—

Outcome results

None listed

Source: EU CTIS · Data processed: May 23, 2026